AR and prostate cancer: LAQ824 (one of the HDACIs) can reduce wild-type and mutated AR through HSP90 inhibition when treated in androgen-dependent and -independent prostate cancer cell lines, and in LNCaP cells, the drug also affected androgen-induced prostate-specific antigen (PSA) production, blocked cell proliferation and resulted in apoptosis [13].